News

In COPD Treatment, GlaxoSmithKline Reports Positive Results in Incruse® Ellipta® Studies

GlaxoSmithKline recently announced in a press release positive data from two head-to-head trials comparing the safety and efficacy of its product Incruse® Ellipta® (umeclidinium) to two available bronchodilator therapies, tiotropium (trial 201316) and glycopyrronium (trial 201315), as a treatment option for patients with chronic obstructive pulmonary disease (COPD).

GSK and Theravance Submit Supplemental Japanese New Drug Application for Relvar Ellipta for COPD Management

GlaxoSmithKline (GSK) and Theravance, Inc. recently announced in a press release their plans to file for a joint-supplemental Japanese New Drug Application (sJNDA) for their collaboratively developed chronic obstructive pulmonary disease (COPD) treatment, Relvar® Ellipta® (fluticasone furoate “FF”/vilanterol “VI” or “FF/VI” or Breo Ellipta). The partners aim to submit the application…

New Mobile COPD Daily Assessment Solution From Bracket Reaches Key Certification Milestone

Bracket, an electronic Clinical Outcomes Assessments (eCOA) provider, recently announced that the company has completed a key certification along with partner Evidera™ for the EXACT patient daily e-Diary to be used on the Android mobile platform. By reaching this certification milestone, the Bracket eCOA solution is now the only certified provider of this technology for use on…

Theravance/Mylan Initiate Phase III Clinical Trial of Revefenacin for COPD

Theravance Biopharma, Inc. and Mylan MYL recently announced the commencement of a new phase III clinical program to evaluate revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) being developed to treat chronic obstructive pulmonary disease (COPD). The Phase III clinical program involves two replicate, randomized, placebo-controlled, double-blind, parallel-group,…